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PROVE IT–TIMI 22 Investigators. Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After
an Acute Coronary Syndrome in the PROVE IT–TIMI 22 Study. J Am Coll Cardiol 2006;47:2326–31.Explanation of CorrectionDuring subsequent analyses of the PROVE IT–TIMI 22 study database, we discovered an error in the original coding that
incorrectly counted the primary endpoint of interest for this manuscriptdthe ﬁrst occurrence of hospitalization for heart
failure.
As a result, the original coding did not account for all episodes of hospitalization for heart failure present in the database. In
addition, the coding did not appropriately identify the timing of ﬁrst occurrence of hospitalization for heart failure in all
subjects. This issue led to an underestimate in all groups irrespective of statin or BNP status.
Using the correct coding, we have repeated all analyses presented in this manuscript. We provide a corrected version of the
Results section for the Abstract and Body Text as well as updated ﬁgures to reﬂect these changes.
Even though the correct coding numerically changes most of the results in the manuscript, there were no qualitative
differences based on the updated results. All the analyses examining the relationships between atorvastatin, BNP, and
hospitalization for heart failure reported in the original are consistent with the updated coding. Therefore, our discussion and
conclusions remain valid and have not been amended.AbstractResults.Treatment with atorvastatin 80 mg signiﬁcantly reduced the rate of hospitalization for HF (2.3% vs. 3.9%, hazard
ratio [HR]: 0.64, 95% conﬁdence interval [CI]: 0.45 to 0.91, p ¼ 0.012) independently of a recurrent myocardial infarction
or prior history of HF. The risk of HF increased steadily with increasing quartiles of BNP (HR: 2.45, 95% CI: 1.33 to 4.52,
p ¼ 0.004) for the highest quartile compared with the lowest). Among patients with elevated levels of BNP (>80 pg/ml),
treatment with atorvastatin signiﬁcantly reduced the risk of HF compared with pravastatin (HR: 0.50, 95% CI: 0.27 to 0.93,
p ¼ 0.028). A meta-analysis of four trials that included 27,546 patients demonstrates a 27% reduction in the odds of
hospitalization for HF with intensive statin therapy.BodyResults. BENEFIT OF INTENSIVE STATIN THERAPY OF HF. This analysis included all 4,162 patients enrolled in the PROVE
IT–TIMI 22 study. As previously described, patients were enrolled a median of seven days after onset of their index event, and
there were no differences between treatment groups in terms of age, gender, index diagnosis, or rates of prior myocardial
infarction, revascularization, diabetes, or hypertension (1). There were also no differences in the rate of prior HF between
treatment arms (3.2% for atorvastatin vs. 3.5% for pravastatin, p ¼ NS), the rate of ST-segment elevation myocardial
infarction (35.6% vs. 33.4%, p ¼ NS), or the rate of PCI for the index event (68.7% vs. 69.1%, p ¼ NS).
Treatment with atorvastatin 80 mg was associated with a signiﬁcant 36% reduction in the rate of hospitalization for HF (2.3%
vs. 3.9% [HR: 0.64, 95% CI: 0.45 to 0.91, p ¼ 0.012]) (Fig. 1). This reduction in the risk of HF was not attenuated when
controlling for recurrent myocardial infarction (HR: 0.68, 95% CI: 0.48 to 0.96, p ¼ 0.030) or a history of prior HF (HR:
0.63, 95% CI: 0.44 to 0.90, p ¼ 0.011). The beneﬁt of atorvastatin 80 mg was similar after excluding all patients (n ¼ 40) who
developed HF after having suffered a recurrent myocardial infarction or recurrent ischemia requiring hospitalization or
revascularization (HR: 0.54, 95% CI: 0.35 to 0.84, p ¼ 0.006). The beneﬁt of intensive statin therapy was also similar when
the ﬁrst 30 days after randomization were included in the analysis (HR: 0.68, 95% CI: 0.49 to 0.93, p ¼ 0.016).
BNP AND THE RISK OF HF.Compared with those without subsequent hospitalization for HF, patients who developed HF had
higher baseline levels of BNP (median 55 vs. 31 pg/ml, p < 0.001) and were more likely to have a concentration of BNP
>80 pg/ml (39.0% vs. 18.2%, p < 0.001). The concentration of BNP showed a signiﬁcant graded relationship with the risk of
HF, with a signiﬁcantly higher risk of HF among patients in the highest (BNP >65 pg/ml) compared with the lowest quartile
(BNP <15 pg/ml, adjusted HR: 2.45, 95% CI: 1.33 to 4.52, p ¼ 0.004).
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Figure 1 Cumulative Incidence of the Hospitalization for Congestive Heart Failure
Intensive statin therapy with atorvastatin 80 mg, as compared with moderate statin therapy with pravastatin 40 mg, reduced the risk for hospitalization for congestive
heart failure by 45% (hazard ratio: 0.64, 95% conﬁdence interval: 0.45 to 0.91, p¼ 0.012). This beneﬁt was not attenuated after controlling for recurrent myocardial infarction or
prior history of heart failure. HR ¼ hazard ratio.
Figure 2 Cumulative Incidence of Hospitalization for Congestive Heart Failure Stratiﬁed Into Four Groups
Groups include: 1) patients with normal baseline levels of B-type natriuretic peptide (BNP) (>80 ng/l) on atorvastatin; 2) patients with normal BNP on pravastatin; 3) patients
with elevated levels of BNP (>80 ng/l) on atorvastatin; and 4) patients with elevated BNP on pravastatin. Comparisons between groups were performed using a Cox
proportional hazard model that included age, sex, diabetes mellitus, hypertension, smoking, body mass index, creatinine, index event, percutaneous coronary intervention for
index event. Among patients with elevated levels of BNP, treatment with atorvastatin signiﬁcantly reduced the risk of heart failure. *Hazard ratio [HR]: 4.62, 95%
conﬁdence interval [CI]: 2.80 to 7.63, p < 0.001 compared with BNP 80/atorvastatin; **HR: 2.30, 95% CI: 1.24 to 4.28, p ¼ 0.008 compared with BNP <80/atorvastatin;
***HR 1.40, 95% CI: 0.88 to 2.24, p ¼ 0.160 compared with BNP <80/atorvastatin. Atorva ¼ atorvastatin; Prava ¼ pravastatin.
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Figure 3 Beneﬁt of Intensive Statin Therapy Versus Moderate Statin Therapy in Reducing the Risk of Hospitalization for Heart Failure
This analysis in 27,546 patients includes the pravastatin or atorvastatin evaluation and infection trial–thrombolysis in myocardial infarction 22 (PROVE IT–TIMI 22) (1), treating
to new targets (TNT) (2), A to Z (11), and incremental decrease in endpoints through aggressive lipid lowering (IDEAL) (3) studies.
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1729INTENSIVE STATIN THERAPY ANDBNP.There was no difference in baseline levels of BNP between treatment arms (31 vs. 32 ng/l,
p ¼ NS). When examined by elevated (>80 pg/ml) or normal (>80 pg/ml) baseline levels of BNP and treatment arm,
patients with elevated baseline levels (>80 pg/ml) of BNP randomized to pravastatin had the highest rate of hospitalization
for HF (8.6%) followed by patients with an elevated BNP randomized to atorvastatin (4.1%), patients with normal BNP
randomized to pravastatin (2.8%), and then patients normal baseline levels of BNP randomized to atorvastatin were at 1.8%
(Fig. 2).
Assignment to atorvastatin signiﬁcantly reduced the risk of the development of HF among patients with elevated levels of
BNP (HR: 0.50, 95% CI: 0.27 to 0.93, p ¼ 0.028). Although patients with such elevated levels of BNP had a greater absolute
reduction in the risk of HF (4.5%) with intensive statin therapy than patients with low BNP (1.0%, HR: 0.72, 95% CI: 0.45
to 1.14, p ¼ 0.16), formal statistical testing for an interaction of BNP with the effect of treatment was not signiﬁcant
(p interaction ¼ 0.36).
META-ANALYSIS OF INTENSIVE STATIN THERAPY TRIALS. A meta-analysis of the four published large, randomized trials that
compared intensive statin therapy with moderate statin therapy and that reported the rates of congestive HF demonstrates
a highly signiﬁcant 27% reduction in the odds of hospitalization for HF in (n ¼ 27,546, OR: 0.73, 95% CI: 0.64 to 0.84,
p < 0.001) (chi-square for heterogeneity ¼ 1.22 [degrees of freedom ¼ 3], p ¼ 0.747) (Fig. 3).
http://dx.doi.org/10.1016/j.jacc.2013.09.002
